Obicetrapib

Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%). As of 2023, it is in a Phase III trial.

History
Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017. In 2020, Amgen licensed the drug to NewAmsterdam Pharma.